Importantly, inhibition of SATB2/CBP transcriptional activity by the CBP inhibitor C646 significantly suppressed GSC proliferation and GBM tumor growth, indicating that targeting SATB2/CBP may be an effective therapeutic strategy to improve GBM treatment. This evidence concerns the gene SATB2 and glioblastoma.